Episode 30 (#4 of 4): Challenges of Implementing Evidence-Based Guidance for IgA Nephropathy

Dr. Rizk is joined by Suneel Udani, MD (Nephrology Associates of Northern Illinois and Indiana, US), to examine challenges in implementing the KDIGO IgAN Guideline in clinical practice and strategies to overcome those challenges.

The experts address a shift in therapeutic goals, including a new paradigm of simultaneous, multi-targeted therapy. They also discuss the need for greater awareness, a more precise diagnostic approach, key insights for recent trials, and areas for future research.

Episode 29 (#3 of 4): How I Treat IgA Nephropathy: Lessons from the Case Files

Dr. Rizk is joined by Gaia Coppock, MD (University of Pennsylvania School of Medicine, US), and Andrew Lazar, MD (University Hospitals of Cleveland, US), to walk through challenging IgAN cases that bring the new KDIGO recommendations to life.

This practical case discussion explores risk stratification, treatment decision making, and common gray areas clinicians face when managing IgAN. The conversation highlights where the evidence is clear and where thoughtful individualization still matters.

Episode 25 (#2 of 4): Treatment Revolution in IgA Nephropathy

Dr. Rizk is joined by Shikha Wadhwani, MD (University of Texas Medical Branch, US), for a conversation on the treatment revolution in IgAN.

They discuss how breakthroughs in understanding disease pathophysiology are fueling a wave of new therapies that go beyond traditional supportive care. Key topics include what’s changed since the KDIGO 2021 Guideline, the four-hit hypothesis and its role in driving novel therapies, key factors to consider when selecting treatments, and the evolving role of traditional approaches alongside newer agents.

Episode 24 (#1 of 4): Overview of the Latest Guidance in IgA Nephropathy Management

Dr. Rizk is joined by Brad Rovin, MD (Ohio State University, US), Co-Chair of the 2025 KDIGO IgAN/IgAV Guideline, for a deep dive into the latest updates in patient care.

Their conversation explores the key takeaways from the new guideline, the critical role of kidney biopsies in diagnosis and prognosis, the use of the IgAN prediction tool for risk assessment, and the updated thresholds and treatment goals aimed at improving outcomes.

This series was supported by Travere.